NCT01504256 - Catumaxomab for Treatment of Peritoneal Carcinomatosis in Patients With Gastric Adenocarcinomas | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

March 31, 2017

Study Completion Date

July 31, 2017

Conditions

Gastric Adenocarcinoma With Peritoneal CarcinomatosisSiewert Type II Adenocarcinoma of Esophagogastric Junction With Peritoneal CarcinomatosisSiewert Type III Adenocarcinoma of Esophagogastric Junction With Peritoneal Carcinomatosis

Interventions

DRUG

catumaxomab, Fluorouracil, leucovorin, oxaliplatin, docetaxel

"Catumaxomab: 4 intraperitoneal infusions of catumaxomab at an escalating dose of 10µg (d0), 20µg (d3), 50µg (d7), and 150µg (d10)~and 7 days after the last catumaxomab infusion~FLOT; 6 cycles q2w: Fluorouracil 2600 mg/m² as 24h infusion (d1) , leucovorin 200mg/m² (d1), oxaliplatin 85 mg{m² (d1), docetaxel 50 mg/m² (d1)"

DRUG

Fluorouracil, leucovorin, oxaliplatin, docetaxel

"FLOT; 6 cycles q2w:~Fluorouracil 2600 mg/m² as 24h infusion (d1) leucovorin 200mg/m² (d1) oxaliplatin 85 mg{m² (d1) docetaxel 50 mg/m² (d1)"

Trial Locations (1)

04103

Prof. Dr. F. Lordick, Leipzig